{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:35:00Z","timestamp":1793730900952,"version":"4.6.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inborn Errors of Immunity (IEI) are monogenic disorders that predispose patients to infections, autoimmunity, atopy, and malignancies. Severe Th2-driven atopic dermatitis and asthma are common in several IEIs, including DOCK8 deficiency, STAT3 loss-of-function, and Wiskott\u2013Aldrich syndrome, often refractory to conventional therapies. Dupilumab, a monoclonal antibody targeting IL-4R\u03b1, has shown promise in managing recalcitrant atopic dermatitis and asthma, but data in immunocompromised pediatric populations remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-center, retrospective observational cohort study with prospective follow-up of ten pediatric patients with genetically confirmed IEI and atopic manifestations. Patients received subcutaneous dupilumab (300 mg every 4 weeks for atopic dermatitis; every 2 weeks for severe asthma). Outcomes were assessed using the Eczema Area and Severity Index (EASI), Dermatology Life Quality Index (DLQI), Childhood Asthma Control Test (C-ACT), eosinophil counts, and infection frequency across four time points (baseline, 6 months, 12 months, &amp;gt;18 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort included ten patients (6 males, 4 females) with mutations in DOCK8 (n=5), CARD11 (n=2), STAT3 LOF (n=1), ADA (n=1), and PEPD (n=1). Of ten patients, nine received dupilumab for atopic dermatitis. Baseline EASI and DLQI scores were 34.33 and 25.0, respectively. Following dupilumab therapy, mean EASI decreased to 2.67 (p&amp;lt;0.001) and DLQI improved to 2.67 (p&amp;lt;0.001), with sustained response observed over 18 months. Peripheral eosinophil counts declined from 2.0\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L to 0.45\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L (p&amp;lt;0.001). One patient with severe asthma achieved C-ACT improvement from 10 to 26 with no subsequent exacerbations. Treatment was well-tolerated, with only mild conjunctivitis or transient hypereosinophilia reported. Notably, skin infections resolved, and no systemic or opportunistic infections were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dupilumab is a safe and highly effective therapeutic option for pediatric patients with IEI-associated atopic manifestations, improving clinical outcomes, quality of life, and infection profile while preserving immune function. These findings support broader application of dupilumab in patients with IEI and warrant further investigation in larger, multicenter studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1715919","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:29:44Z","timestamp":1763706584000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Dupilumab for atopic manifestations in pediatric patients with inborn errors of immunity: efficacy and safety in a genetically diverse cohort"],"prefix":"10.3389","volume":"16","author":[{"given":"Najla","family":"Alsediq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thekra","family":"Algholaiqa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghadah","family":"Alnami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman N.","family":"AlJaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e20250002","DOI":"10.70962\/jhi.20250002","article-title":"The 2024 update of IUIS phenotypic classification of human inborn errors of immunity","volume":"1","author":"Bousfiha","year":"2025","journal-title":"J Hum Immun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.07.026","article-title":"Successful treatment of atopic dermatitis with dupilumab in the setting of X-linked agammaglobulinemia","volume":"10","author":"Fan","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17889","article-title":"Dupilumab treatment of eczema in a child with STAT3 hyper-immunoglobulin E syndrome","volume":"36","author":"Wang","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15397","article-title":"Severe eczema in Wiskott-Aldrich syndrome-related disorder successfully treated with dupilumab","volume":"41","author":"Alzahrani","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15955","article-title":"Treatment options for DOCK8 deficiency-related severe dermatitis","volume":"48","author":"Ollech","year":"2021","journal-title":"J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e14215","DOI":"10.1111\/pai.14215","article-title":"Use of dupilumab for atopic dermatitis in pediatric and young adult patients with inborn errors of immunity","volume":"35","author":"Zangari","year":"2024","journal-title":"Pediatr Allergy Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.982772","article-title":"Inborn errors of immunity and related microbiome","author":"Hazime","year":"2022","journal-title":"Front Immunol"},{"key":"B8","unstructured":"FDA website\n          \n          \n          \n          2022"},{"key":"B9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jaip.2021.08.042","article-title":"Relieving job: Dupilumab in autosomal dominant STAT3 hyper-IgE syndrome","volume":"10","author":"Staudacher","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15453","article-title":"Prurigo-like atopic dermatitis in a child with CARD11-associated severe combined immunodeficiency successfully treated with dupilumab","volume":"41","author":"Gualdi","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00751-4","article-title":"Efficacy of dupilumab for controlling severe atopic dermatitis in a patient with hyper-IgE syndrome","volume":"40","author":"L\u00e9vy","year":"2020","journal-title":"J Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2022.08.004","article-title":"Efficacy of dupilumab for the treatment of severe skin disease in cytotoxic T lymphocyte antigen-4 insufficiency: A role of type 2 inflammation","volume":"2","author":"Arruda","year":"2022","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2022.4288","article-title":"Successful dupilumab therapy for atopic dermatitis in a patient with X-linked agammaglobulinaemia","volume":"32","author":"Fujishima","year":"2022","journal-title":"Eur J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2021.03.007","article-title":"Treatment efficacy of dupilumab in a hyper-immunoglobulin E syndrome patient with severe atopic dermatitis","volume":"11","author":"Su","year":"2021","journal-title":"JAAD Case Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s10875-024-01837-z","article-title":"Dupilumab in a 9-week-old with netherton syndrome leads to deep symptom control","volume":"45","author":"Vollmuth","year":"2024","journal-title":"J Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1507494","article-title":"Case report: Advanced age at transplantation and pre-emptive treatment with dupilumab in DOCK8 deficiency","volume":"15","author":"Trombello","year":"2025","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000943","article-title":"Atopic manifestations of inborn errors of immunity","volume":"23","author":"Sams","year":"2023","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/all.15647","article-title":"CK-CARE study group. IL-13, periostin and dipeptidyl-peptidase-4 reveal endotype-phenotype associations in atopic dermatitis","author":"Maintz","year":"2023","journal-title":"Allergy"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.11.023","article-title":"Skin TARC\/CCL17 increase precedes the development of childhood atopic dermatitis","volume":"151","author":"Halling","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.01.019","article-title":"Biomarkers in atopic dermatitis","volume":"151","author":"Bakker","year":"2023","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1715919\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:29:47Z","timestamp":1763706587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1715919\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2025.1715919"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1715919","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"article-number":"1715919"}}